In June 2021, the United States Food and Drug Administration approved a new drug called aducanumab (brand name Aduhelm™) for the treatment of patients with Alzheimer’s disease. Aducanumab was approved using the FDA’s “Accelerated Approval pathway”. For basic information about this medication, please see the following article on this website: Aducanumab (Aduhelm™): Basic information What the…